Photobiomodulation improved stereological parameters and sperm analysis factors in streptozotocin-induced type 1 diabetes mellitus

Dadras, Sara; Abdollahifar, Mohammad‐Amin; Nazarian, Hamid; Ghoreishi, Seyed Kamran; Fallahnezhad, Somaye; Naserzadeh, Parvaneh; Jajarmi, Vahid; Chien, Sufan; Bayat, Mohammad

doi:10.1016/j.jphotobiol.2018.06.018

Cited by 9 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the previous studies, using a single intraperitoneal injection of 120 mg/kg STZ [ 23 ], the STZ-induced diabetic mice was constructed successfully, along with an increase in blood sugar, the body weight and testicles weight of DM mice was significantly reduced [ 24 ]. Meanwhile, serious histological damage, including reduced cross-sectional area of spermatogenic tubules and reduced diameter and morphological destruction was caused [ 25 ]. What’s more, reduced spermatogenic cells and sperm count, and increased rate of malformed sperms are detected in DM mice [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of spermidine on ameliorating spermatogenic disorders in diabetic mice via regulating glycolysis pathway

Wang

Luo

et al. 2022

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Diabetes mellitus (DM), a high incidence metabolic disease, is related to the impairment of male spermatogenic function. Spermidine (SPM), one of the biogenic amines, was identified from human seminal plasma and believed to have multiple pharmacological functions. However, there exists little evidence that reported SPM’s effects on moderating diabetic male spermatogenic function. Thus, the objective of this study was to investigate the SPM’s protective effects on testicular spermatogenic function in streptozotocin (STZ)-induced type 1 diabetic mice. Therefore, 40 mature male C57BL/6 J mice were divided into four main groups: the control group (n = 10), the diabetic group (n = 10), the 2.5 mg/kg SPM-treated diabetic group (n = 10) and the 5 mg/kg SPM-treated diabetic group (n = 10), which was given intraperitoneally for 8 weeks. The type 1 diabetic mice model was established by a single intraperitoneal injection of STZ 120 mg/kg. The results showed that, compare to the control group, the body and testis weight, as well the number of sperm were decreased, while the rate of sperm malformation was significantly increased in STZ-induced diabetic mice. Then the testicular morphology was observed, which showed that seminiferous tubule of testis were arranged in mess, the area and diameter of which was decreased, along with downregulated anti-apoptotic factor (Bcl-2) expression, and upregulated pro-apoptotic factor (Bax) expression in the testes. Furthermore, testicular genetic expression levels of Sertoli cells (SCs) markers (WT1, GATA4 and Vimentin) detected that the pathological changes aggravated observably, such as the severity of tubule degeneration increased. Compared to the saline-treated DM mice, SPM treatment markedly improved testicular function, with an increment in the body and testis weight as well as sperm count. Pro-apoptotic factor (Bax) was down-regulated expression with the up-regulated expression of Bcl-2 and suppression of apoptosis in the testes. What’s more, expression of WT1, GATA4, Vimentin and the expressions of glycolytic rate-limiting enzyme genes (HK2, PKM2, LDHA) in diabetic testes were also upregulated by SPM supplement. The evidence derived from this study indicated that the SMP’s positive effect on moderating spermatogenic disorder in T1DM mice’s testis. This positive effect is delivered via promoting spermatogenic cell proliferation and participating in the glycolytic pathway’s activation.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of spermidine on ameliorating spermatogenic disorders in diabetic mice via regulating glycolysis pathway

Wang

Luo

et al. 2022

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…In the previous studies, using a single intraperitoneal injection of 120 mg/kg STZ [21], the STZ-induced diabetic mice was constructed successfully, along with an increase in blood sugar, the body weight and testicles weight of DM mice was signi cantly reduced [22]. Meanwhile, serious histological damage, including reduced crosssectional area of spermatogenic tubules and reduced diameter and morphological destruction was caused [23]. What's more, reduced spermatogenic cells and sperm count, and increased rate of malformed sperms are detected in DM mice [24].In this study, our results were consistent with all of the above literatures, which makes meaningful by exploring the spermatogenic dysfunction in diabetic males forward.…”

Section: Discussionmentioning

confidence: 99%

Effect of Spermidine on Ameliorating Spermatogenic Disorders in Diabetic Mice Via Regulating Glycolysis Pathway.

Wang

Luo

et al. 2021

Preprint

View full text Add to dashboard Cite

Diabetes mellitus (DM), a high incidence metabolic disease, is related to the impairment of male spermatogenic function. Spermidine (SPM), one of the biogenic amines, was identified from human seminal plasma and believed to have multiple pharmacological functions. However, there exists little evidence that reported SPM's effects on moderating diabetic male spermatogenic function. Thus, the objective of this study was to investigate the SPM's protective effects on testicular spermatogenic function in streptozotocin (STZ)-induced type 1 diabetic mice. Therefore, 40 mature male C57BL/6J mice male were divided into four main groups: the control group (n=10), the diabetic group (n=10), the 2.5 mg/kg SPM-treated diabetic group (n=10) and the 5 mg/kg SPM-treated diabetic group (n=10), which was given intraperitoneally for 8 weeks. The type 1 diabetic mice model was established by a single intraperitoneal injection of STZ 120 mg/kg. The results showed that, compare to the control group, the body and testis weight, as well the number of sperm were decreased, while the rate of sperm malformation was significantly increased in STZ-induced diabetic mice. Then the testicular morphology was observed, which showed that seminiferous tubule of testis were arranged in mess, the area and diameter of which was decreased, along with downregulated anti-apoptotic factor (Bcl-2) expression, and upregulated pro-apoptotic factor (Bax) expression in the testes. Furthermore, testicular genetic expression levels of Sertoli cells (SCs) markers (WT1, GATA4) and Vimentin detected that the pathological changes aggravated observably, such as the severity of tubule degeneration increased. Compared to the saline-treated DM mice, SPM treatment markedly improved testicular function, with an increment in the body and testis weight as well as sperm count. Pro-apoptotic factor (Bax) was down-regulated expression with the up-regulated expression of Bcl-2 and suppression of apoptosis in the testes. What’s more, expression of WT1, GATA4, Vimentin and the expressions of glycolytic rate-limiting enzyme genes (HK2, PKM2, LDHA) in diabetic testes were also upregulated by SPM supplement. The evidence derived from this study indicated that the SMP's positive effect on moderating spermatogenic disorder in T1DM mice's testis. This positive effect is delivered via promoting spermatogenic cell proliferation and participating in the glycolytic pathway's activation.

show abstract

Effect of low-level laser therapy on seminiferous epithelium: a systematic review of in vivo studies

et al. 2020

View full text Add to dashboard Cite

Photobiomodulation improved stereological parameters and sperm analysis factors in streptozotocin-induced type 1 diabetes mellitus

Cited by 9 publications

References 48 publications

Effect of spermidine on ameliorating spermatogenic disorders in diabetic mice via regulating glycolysis pathway

Effect of spermidine on ameliorating spermatogenic disorders in diabetic mice via regulating glycolysis pathway

Effect of Spermidine on Ameliorating Spermatogenic Disorders in Diabetic Mice Via Regulating Glycolysis Pathway.

Effect of low-level laser therapy on seminiferous epithelium: a systematic review of in vivo studies

Contact Info

Product

Resources

About